| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $5.68 | - | - |
| Q1'26 | $2.61 | $2.89 | +10.6% |
| Q4'25 | $2.62 | $2.99 | +14.2% |
| Q3'25 | $2.07 | $2.19 | +5.6% |
| Q2'25 | $2.48 | $2.37 | -4.5% |
| Q1'25 | $1.51 | $1.85 | +22.9% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'26 | $2.5B | - | - |
| Q1'26 | $1.9B | $2.0B | +5.7% |
| Q4'25 | $1.8B | $1.9B | +2.0% |
| Q3'25 | - | $1.7B | - |
| Q2'25 | - | $1.9B | - |
| Q1'25 | - | $1.7B | - |
Market Data
CF is currently trading at $116.92, giving CF Industries Holdings, Inc. a market cap of 17.79B and a P/E ratio of 10.1. Today's range spans $113.32–$116.98, with shares opening at $114.88 and moving down $0.02 (0.0%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY) with a news sentiment reading of 82/100.
Over the past year CF has traded between $75.42 and $141.96 - the current price is +55.0% off the 52-week low and -17.6% from the high. 32 analysts cover the stock with a Hold consensus and a mean 12-month target of $125.72 (range $100.00–$195.72), implying upside of +7.5%.
The bullish case for CF is built on complementary signals: 68/100 technical score, BUY designation, and bullish sentiment at 82/100. At $116.92 (in the middle of its 52-week range within $75.42–$141.96), the stock is at a capitalization - 17.79B - where active managers can build meaningful positions without moving the market. (P/E: 10.1) That combination of signal quality and position-buildability makes this one of the more actionable large-cap setups in Basic Materials.
Earnings revision cycles in large-cap Basic Materials names tend to compound: when technicals confirm a BUY thesis (68/100) and news sentiment (82/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $116.92 (in the middle of its 52-week range), CF's position within the $75.42–$141.96 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).